ABSTRACT
The past decade has given us the opportunity to accumulate an increasing amount of data relating to the use of endovascular technology for the treatment of abdominal aortic aneurysms (AAA). The devices continue to be refined, and some have become commercially available, allowing for the widespread application of this treatment. Initial clinical trials have reported high success rates for the endovascular exclusion of AAAs (1–4), but the long-term durability and success of endografts remains suspect, as many early and late failures have been reported (5–7).
